Holen Sie sich die Stockscreener-App
13.52
3.15%
-0.435
Handel nachbörslich:
13.53
0.015
+0.11%
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Discipline and Rules-Based Execution in ENTA Response - Stock Traders Daily
Enanta Pharma's RSV Bet And Immunology Ambitions - RTTNews
Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives - Sahm
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Enanta Pharmaceuticals Q2 2026 Financial Results and Management Discussion – 10-Q Report Highlights - Minichart
ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary - TradingView
Enanta Pharmaceuticals (NASDAQ: ENTA) trims losses on higher HCV royalties and lower R&D - Stock Titan
Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Enanta (ENTA) Reports Strong Q2 Revenue and Progress in Clinical Trials - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q2 FY26 Beat? - GuruFocus
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus - ChartMill
ENANTA PHARMACEUTICALS ($ENTA) Releases Q2 2026 Earnings - Quiver Quantitative
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Weekly Voice
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - marketscreener.com
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan
MSN Money - MSN
Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Behavioral Patterns of ENTA and Institutional Flows - Stock Traders Daily
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Progr - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - BioSpace
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy - MSN
(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ENTA Price Today: Enanta Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ENTA (Enanta Pharmaceuticals Inc.) posts 49 percent narrower Q1 2026 loss than expected, shares fall 3.37 percent on slight revenue decline.Management Guidance - Xã Thanh Hà
How (ENTA) Movements Inform Risk Allocation Models - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus
Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia
Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com
Enanta doses first patient in phase 1 trial of urticaria drug By Investing.com - Investing.com South Africa
Meme Stocks: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn
Are investors bullish on Enanta Pharmaceuticals (ENTA) Stock | ENTA Q4 Earnings: Beats Estimates by $0.40 - Newser
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire
Is Enanta Pharmaceuticals (ENTA) Stock Suitable for 2026 | Price at $13.18, Up 0.27%Size Factor - Newser
Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):